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Objective: While status epilepticus (SE) persisting after two antiseizure agents is called refractory (RSE), 
super-refractory status epilepticus (SRSE) defines SE continuing after general anesthesia. Its prevalence and 
related clinical profiles have received limited attention, and most studies were restricted to intensive care 
facilities. We therefore aimed at describing RSE and SRSE frequencies, and identifying associated clinical 
variables. 
Methods: Between 2006 and 2015, consecutive adult SE episodes were prospectively recorded in a registry. 
Occurrence of RSE and SRSE and their relationship to clinical variables of interest, including outcome, were 
analysed. 
Results: Of 804 SE episodes 268(33.3%) were RSE, and 33(4%) SRSE. Coma induction for SE treatment 
occurred in 79 (9.8%) episodes. Severe consciousness impairment (OR 1.67; 95%CI 1.24–2.46; p=0.001), 
increasing age (OR 1.01, 95%CI 1.01-1.02), and lack of remote symptomatic SE aetiology (OR 0.48; 95%CI 
0.32–0.72) were independently associated with RSE, while severe consciousness impairment (OR 4.26; 
95%CI 1.44-12.60) and younger age (OR 0.96; 95%CI 0.95-0.99) correlated with SRSE; however, most 
SRSE episodes were not predicted by these variables.  Mortality was 15.5% overall, higher in RSE (24.5%) 
and SRSE (37.9%) than in non-refractory SE (9.8%) (p<0.001). 
Significance: SRSE appears clearly less prevalent in this cohort than previously reported, probably since it is 
not restricted to intensive care unit. SRSE emerges in younger patients with marked consciousness 
impairment, pointing to the underlying severe clinical background, but these variables do not predict most 













Status epilepticus (SE) is a potentially severe neurological emergency, with an annual incidence in Europe of 
10–16 per 100.000 population, carrying a risk of major morbidity and mortality [1,2]. Its persistence despite 
first and second-line administration of antiepileptic drugs (AED), referred to as “refractory” SE (RSE), 
occurs in 14 – 46% of cases [3-14]. Super-refractory SE (SRSE) was recently defined as a refractory episode 
continuing despite 24 hours of general anaesthesia [15], and has been reported to occur in 12 – 26% of SE 
and in 13 – 42% of RSE [4,6,7,9,16,17]. Available estimations of both RSE and SRSE incidence primarily 
rely on retrospective studies conducted in Intensive Care Units (ICUs) [3,6,16,18,19] or in developing 
countries  [9,10,17], with heterogeneous designs accounting for their variability. Only one prospective 
hospital-based study from Argentina reports a lower SRSE rate (5%) [8]. 
Management of RSE and SRSE is challenging, as it requires balancing the benefit and risks of treatment 
used to rapidly control seizures [20]. Recent data reported that drug-induced coma may be associated with a 
poorer outcome [6,21,22]. However, other studies challenge this view, considering that inadequate or delayed 
treatment could represent an independent risk of mortality [23,24]. Short-term SE mortality in Europe ranges 
between 11-37% in hospital-based studies, including ICU-limited settings [3,4,6,12,14]. The main predictors 
of fatal SE are older age, life-threatening aetiologies, and possibly the degree of impairment of consciousness 
and SE duration [3,12,13]. Mortality rates increase up to 15 – 54% among patients with RSE and SRSE [3-
6,9,11,13,19,24], stressing the severity of these conditions. 
A refined knowledge of RSE and SRSE epidemiology may help individualizing therapy according to the 
episode prognosis. Therefore, our primary aim was to determine the frequency of RSE and SRSE in a large 
hospital-based cohort population, not limited to the ICU, and subsequently, to identify clinical variables, 
including outcome, associated with their occurrence. 
 
METHODS 
Study design and setting 
This is a retrospective analysis of prospectively collected data from a registry of consecutive adult patients 
(≥16 years old) with SE treated in our hospital (CHUV) between 1st April 2006 and 31st July 2015 (112 
months). The CHUV represents the primary facility for the urban area of Lausanne (about 250’000 
population) and a tertiary referral centre for a population of about 1’000’000. The registry is approved by the 
Commission cantonale d’éthique de la recherche sur l’être humain (CER-VD), a member of the Swiss 
Association of Ethics Committees; given its purely observational nature, informed consent is waived. The 
study was conducted according to the ethical principles of the Helsinki Declaration. Personal data were 
coded .  
Patients and SE definition 
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All patients aged ≥16 years with SE are prospectively enrolled in our registry, the only exclusion criteria 
being a postanoxic aetiology, as previously described [12]. SE was defined as the occurrence of continuous 
or repetitive seizures, between which there is incomplete recovery of baseline clinical conditions for at least 
30 minutes (until 2008) or 5 minutes (since 2008) [25]. SE episodes were diagnosed clinically by board 
certified neurologists, and confirmed, whenever necessary, with electroencephalography (EEG). RSE was 
defined if first- and second line antiepileptic treatments failed to control seizures, without a given time span, 
implying the need to prescribe an additional specific treatment [12]; for the purpose of this study, RSE does 
not include SRSE if not otherwise specified. SRSE was defined as continuous or recurrent seizures lasting 24 
hours or more following administration of a first course of anesthetics for therapeutic coma induction [15]. 
Variables definition 
The following items were prospectively recorded: demographics (gender and age, treated as a continuous 
variable), previous seizures, time to first SE treatment start and other relevant clinical data were noted on 
admission. Aetiology was classified according to the International League Against Epilepsy (ILAE) criteria, 
as acute symptomatic, remote symptomatic, progressive symptomatic, and idiopathic/cryptogenic [26]. SE 
causes were further categorized as potentially fatal aetiology or not, according to a previously established list 
of aetiologies known to be associated to death independently from SE [27]. Moreover, we defined 
inflammatory SE as caused by proven acute inflammation of the brain parenchyma, with or without 
involvement of meninges, associated with neurologic dysfunction, as previously reported [32]. Level of 
consciousness before treatment was classified as alert, confused or somnolent (arousable towards clear 
clinical contact), versus stuporous (arousable, but without contact), or comatose. The latter two were grouped 
as “severe impairment of consciousness”. SE semiology was defined by the worst clinical seizure in the 
given episode, and classified as simple partial (focal without impairment of consciousness), absence, 
myoclonic (related to genetic generalized epilepsy), complex partial (focal with impairment of 
consciousness), generalized convulsive (GCSE), or non-convulsive SE in coma (NCSEC). For each episode, 
the validated SE severity score (STESS) was calculated on admission, and categorized as < 3 versus  ≥3 [28]. 
Prescribed AEDs (including anaesthetic drugs), load dosages and sequence of drug’s administration, 
including anaesthetics used for therapeutic coma induction, were recorded. The latency between onset of SE 
and treatment (time to treatment, TTT) was categorized as < 1 h versus ≥1 h. SE duration was categorized as 
lasting less or more than 30 min. Three possible outcomes were retrieved at hospital discharge: return to 
baseline clinical condition, new neurological disability (as compared to pre-SE clinical status), or death. The 
only retrospectively assessed variable was the Charlson Comorbidity Index (CCI, 17-item version) [29] and 
categorized in two groups: CCI = 0 versus CCI ≥ 1. 
Procedures 
Routine practice included complete electrolytic, metabolic, and hematologic work-up. Brain imaging 
(computed tomography and/or magnetic resonance) was performed in the vast majority of patients. All 
5 
 
subjects had at least one EEG recorded within the first 18 hours following hospital admission, while all those 
undergoing pharmacologically induced coma had continuous EEG monitoring. Follow-up studies, including 
infectious or inflammatory panels and lumbar puncture, were performed as clinically required. SE treatment 
followed the in-house protocol, and  included following intravenous administrations: as first line, a slow 
bolus of lorazepam 0.1 mg/kg, clonazepam 0.015 mg/kg, or midazolam 0.15 mg/kg; as second line, 
phenytoin 20 mg/kg, or valproate 20-30 mg/kg, levetiracetam 20-30 mg/kg, or lacosamide 400 mg; as third 
line, propofol 2 mg/kg followed by 2–5 mg/kg/h and/or midazolam 0.2 mg/kg followed by 0.2–1.0 mg/kg/h, 
or thiopental 2-5 mg/kg followed by 1–5 mg/kg/h (see also [30]). The third line was monitored by continuous 
EEG, with seizure suppression or burst suppression as target, and maintained for at least 24 h before weaning 
off the anaesthetics over 6–12 hours. Additional treatments, such as oral topiramate and pregabalin, 
intravenous ketamine, ketogenic diet, immunomodulation, or hypothermia, were prescribed in selected cases. 
Patients were managed in intermediate care units, or in ICU if they needed coma induction.  
Review of the literature 
We searched for articles and abstracts on refractory and super-refractory status epilepticus. The search 
strategy was part of an ongoing systematic review, recently registered at PROSPERO International 
prospective register of systematic reviews with registration number  CRD4201603334.  Data on study 
design, setting, length of study period, as well as RSE and SRSE frequencies were reported in a table, 
including the present study. 
Statistical analyses 
We performed exploratory univariable analyses using Pearson χ2, two-tailed Fisher’s exact, Student t-test or 
Mann-Whitney U tests, as appropriate. Stepwise multivariable logistic regression analyses including 
variables associated with p < 0.15 in univariable analyses were then conducted. The final models were 
validated using the Hosmer-Lemeshow test. We estimated the 95% confidence intervals (CI) on RSE and 
SRSE frequencies using an exact binomial distribution. Calculation were performed with the STATA 
software (version 12) (StataCorp LP, College Station, TX, U.S.A.). 
 
RESULTS 
Patients and demographics 
Eight hundred and four SE episodes (affecting 664 patients) were consecutively recorded in the registry 
during the study period; 323 (48.6%) occurred in women, while 286 patients (43.0 %) had suffered previous 
seizures; mean age was 61 ±18.6 years (range: 16 – 95 years). SE lasted <30 minutes in only 59 (7.3%) 
cases. SE aetiology was acute symptomatic in 454 episodes (56.5%), and categorized as potentially fatal in 
380 (47%). Fifty-five SE episodes were related to an acute inflammatory aetiology. Two-hundred-sixty-eight 
(33.3%, 95% CI 30 – 37) episodes were classified as RSE (not including SRSE) and 33 (4.1%, 95% CI 2.5 – 
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5.7) as SRSE. A coma induction with mechanical ventilation was necessary in 83 (10.3%) SE, including all 
SRSE (100%), 46 RSE (17%), and four non-refractory SE (0.8%, due to SE treatment protocol violation) 
(Figure 1). While SRSE developed in 11% of  refractory SE, its frequency raised to 40% among the subset 
of intubated patients. 
Clinical variables 
Comparisons between NRSE and RSE (including SRSE), and between RSE and SRSE are shown in Tables 
1 and 2. Stepwise multiple logistic regressions showed that a severe consciousness impairment before 
treatment, increasing age, and the lack of remote symptomatic aetiology were independently associated with 
RSE.  Overall, episodes in patients aged ≥65 years, with a severe impairment of consciousness and an 
aetiology other than “remote symptomatic” showed a likelihood of 49% (95% CI: 41 – 56%) to develop 
RSE, while episodes without these three variables had a likelihood of 87% (95% CI: 70 – 96%) to be non-
refractoy. SRSE was independently associated to severe impairment of consciousness and younger age. The 
likelihood to develop SRSE was 23% (95% CI: 15-33%) for patients < 65 years old presenting a severe 
impairment of consciousness at SE onset. 
Considering the 55 SE episodes related to an acute inflammatory aetiology (infectious or autoimmune), a 
higher proportion was found among SRSE episodes: 28 (6%) non-refractory SE, 21 (8%) RSE and 6 (18%) 
SRSE episodes (p= 0.01, χ2). Also, mean age of SE episodes related to acute inflammatory aetiology was 
significantly lower than that of episodes due to other aetiologies, respectively 54±19.9 and 61.5±18.5 years 
old (p=0.005, t-test). 
Outcome at hospital discharge 
Of the 664 incident patients, 103 (15.5%) died during their hospital stay; 37 of them (5.6%) during ongoing 
SE. Mortality among RSE (249 incident patients, including SRSE), at hospital discharge or during ongoing 
SE, was significantly higher when compared to non-refractory episodes (Table 1). At hospital discharge, 
return to baseline occurred less often in RSE (38%) and SRSE (8%) (p<0.001, χ2), and a new disability was 
also more frequent after RSE (28%) and SRSE (43.7%) (p<0.001, χ2), as compared to non-refractory SE. 
Previously published data, addressing RSE and SRSE, are summarized in table 3. 
 
DISCUSSION 
This study, conducted on a large adult cohort not restricted to ICU, shows that while RSE developed in 
33.3% (37% including SRSE), which appears in line with previous estimations, SRSE occurred in only 
4.1%, which is clearly lower than the majority of recent data from other settings. Severe impairment of 
consciousness, lack of a remote symptomatic aetiology and increasing age were independently associated 




Our findings on RSE prevalence are in line with recently reported studies not limited to ICU [4,5,7,8,13] 
(table 3); yet, only 11% of RSE episodes fulfilled SRSE criteria. This contrasts with the few surveys 
addressing the frequency of SRSE, reporting a range of 12-26% [6,7,16,17], with wide confidence intervals 
due to small samples (table 3).  Some of these studies were conducted in ICUs [6,16], while others in 
developing regions [9,17] where underlying infections are very frequent, implying possible selection biases. 
Our low SRSE prevalence might also reflect the relatively conservative therapeutic approach used in our 
centre, with a stepwise escalation of additional antiepileptic drugs (AEDs) and coma-induction in only a 
selected subgroup of RSE, in line with several expert opinions and recommendations [20,31]. To date, only 
one hospital-based study from Argentina reported a similarly low frequency of SRSE (5%, 95%CI 2.7%-
7.3%) [8], supporting the finding that SRSE is a relatively uncommon condition in unselected cohorts. 
We observed that short-term mortality was significantly higher in refractory SE episodes, respectively 24.5% 
and 37.9% among RSE and SRSE patients, broadly in line with most published data [4,5,18,19,24]. 
However, these figures are considerably higher than those recently reported from Finland, with respectively 
6% and 10% short-term mortality in RSE and SRSE [16]. This might result from a mortality assessment 
performed before an early transfer to another hospital in this last study. In our cohort, one-third of deaths 
occurred during SE, but this rose to 73% in SRSE, suggesting greater severity of the conditions underlying 
SRSE. Nearly half of surviving RSE patients had a new handicap at discharge, and again disability was more 
frequent among RSE and SRSE patients, in line with previous studies [4,12,14]. 
Multivariable logistic regressions showed an independent association between a severe impairment of 
consciousness on admission and refractory SE. This finding is comparable to previous series [3,5,12,14], and 
likely reflects the severity  of the underlying brain insult. Acute symptomatic aetiologies as a whole were not 
independently associated with RSE, in contrast with previous studies [3,12], probably because this category 
encompasses a wide spectrum of causes, including relatively benign metabolic disturbances or AED 
withdrawal. Remote symptomatic causes were found to be protective for RSE, suggesting that a static remote 
brain injury is less likely to trigger the process of SE refractoriness than acute brain insults. 
Some previous data imply that young subjects may be at higher risk for very severe SE episodes [9,14], a 
finding confirmed in our analysis. How younger age leads to severe refractoriness is unclear, but recent 
studies suggest that this may represent a surrogate of inflammatory auto-immune causes that may be 
relatively frequently associated with SRSE [14,24,32]. Accordingly, a post-hoc analysis in our study showed 
that inflammatory aetiologies were significantly more frequent amongst SRSE episodes and younger 
subjects. 
The variables identified in the logistic regressions allow a prediction of about one in two patients who will 
develop an RSE episode, but only one in five developing SRSE. It is thus striking that relatively few clinical 
differences are observed on admission between patients developing RSE or SRSE as compared to non-
refractory episodes, suggesting that important biological substrates of SE refractoriness remain undetected. 
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Recent studies have stressed the epileptogenic effect of neuroinflammation and its dependence on genetically 
mediated mechanisms [33,34], this is supported by experimental models [35]. Also, a low serum albumin 
level at SE onset was recently shown to be a predictor of RSE [3]. The search for further biomarkers could 
open up perspective in the identification of new therapeutic targets. While co-morbidities were not 
considered in predictive models of SE refractoriness so far, we did not find any significant role. 
Our study has some limitations. Firstly, it was a retrospective analysis of prospectively collected data. 
Therefore, only associations and not causation can be inferred from our findings. However, all clinical 
variables, except co-morbidities, were chosen a priori and collected prospectively, following a consistent 
protocol over years. While co-morbidities were not considered in predictive models of SE refractoriness so 
far, we did not find any significant role. Secondly, our cohort reflect the recruitment of a tertiary centre, 
potentially concentrating more severe SE episodes, and accounting for a higher short-term mortality (15.5%) 
than that reported in European population-based studies (i.e. 7.6-9.3%) [1,2]. Moreover, an survival bias 
could influence the demographics in the different subgroups, if patients with extremely severe SE would die 
prior to their admission; however, in our experience, SE patients very rarely die out of hospital. Thirdly, 
accordingly to the observational design of our study, decision on coma induction for SE treatment relied on 
patient’s caregiver. Previous studies including this cohort confirm a similar low rate of coma-induction, 
implying generally accepted guidelines amongst CHUV clinicians on a step-wise SE treatment [22, 12, 28]. 
Thus, these findings may be applied to hospital settings with an analogous therapeutic approach of SE. 
Fourth, the database for the present study lacked data on treatment compliance towards recommendations, 
and therefore we did not analyze this aspect; of note, a subgroup analysis of this cohort showed that 
treatment appropriateness did not influence clinical outcome [30]. Finally, continuous EEG  was not 
performed systematically after electro-clinical resolution of SE, potentially resulting in undetected non-
convulsive SE recurrence. However, we believe this risk to be low since most patients underwent repetitive 
EEGs and all SRSE patients were monitored with continuous EEG. 
In conclusion, to our knowledge this represents by far the largest cohort of adult SE patients prospectively 
collected over more than a 9-year period, not restricted to an ICU environment or to settings in developing 
regions labelled with very high proportions of infections. One-third of SE episodes became refractory to first 
and second line treatments, while SRSE remained relatively rare, affecting only 4% of all SE episodes. SE 
refractoriness is likely to be multifactorial with still largely unknown mechanisms. Further studies are needed 
in order to refine a predictive model of SE super-refractoriness, ideally delineating plausible biological and 
genetic biomarkers; this may prove very useful for patient care in this conditions, still hampered by 
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Table 1. Demographics and clinical features in non-refractory and refractory SE (with super-refractory SE included) 
 Univariate analysis 
 





( n=301)  p-value Test  OR  95% CI  P-value 
 
Demographics*                  
   Incident SE patients (nr, %) 415  62.5%  249  37.5%           
   Age (years) (mean, SD) 60  ±19  62  ±19  0.13 Student t  1.01  1.01-1.02  0.039  
   Female gender (nr, %) 206  49.6%  117  47.0%  0.508 Pearson χ2        
Earlier seizures (nr, %) 192  45.9%  94  37.9%  0.097 Pearson χ2        
Charlson Comorbidity Index 
(CCI)   (median [range]) 1  0-12  1  0-12  0.13 U-test 
 
     
 
   CCI 0 (nr, %) 210  41.7%  103  34.2%           
   CCI ≥1 (nr, %) 293  58.3%  198  65.8%  0.034 Pearson χ2      NS  
Etiology according to ILAE (nr, %)                  
   Acute symptomatic 278  55.3%  176  58.5%           
   Remote symptomatic 113  22.5%  38  12.6%     0.48  0.32 – 0.72  <0.001  
   Progressive symptomatic 79  15.7%  63  20.9%           
   Cryptogenic/idiopathic 33  6.5%  26  8.6%  0.001 Pearson χ2      NS  
Potentially fatal etiology (nr, %) 223  44.3%  160  53.2%  0.015 Pearson χ2      NS  
Consiousness at SE onset (nr, %)                  
  Alert, confused or somnolent 239  47.4%  108  35.9%    
 
     
 
  Stuporous or comatose 264  52 %  193  64.1%  <0.001 Pearson χ2 
 
1.67  1.24 – 2.46  0.001 
 
SE types (nr, %)          
  
     
 
  Simple partial 99  19.7%  41  13.6%   
  
     
 
  Absence 7  1.4%  1  0.3%   
  
     
 
  Complex partial 159  31.6%  77  26.6%   
  
     
 
Generalized myoclonic  2  0.4%  0      
  
     
 
  Generalized convulsive 227  45.1%  156  51.8%   
  
     
 
  Nonconvulsive SE in coma 9  1.8%  26  8.6%  <0.001 Fisher 
 
    NS 
 
STESS ≥ 3 (nr, %) 242  48%  172  57.1%  0.013 Pearson χ2 
 
     
 
Time to treatment > 1 h (nr, %) 303  60.2%  192  63.8%  0.317  
 




Intubation for treatment (nr, %) 4  0.8%  79  26.2%  <0.001 Pearson χ2 
 
     
 
Outcome at discharge (nr, %)                  
   Returned to baseline  321  63.8%  106  35.2%           
   New handicap 141  28.0%  133  44.2%           
   Death** 41  9.8%  62  25.0%  <0.001 Pearson χ2        
  Death during SE (nr, %) 9  22%  28  45.2%  <0.001 Fisher 
 
     
 
                
SD, standard deviation; CI, confidence interval; SE, status epilepticus; STESS, status epilepticus severity score. 
* Demographics and mortality frequency was calculated according to the number of the incident patients. 
** Hosmer–Lemeshow goodness-of-fit test for the final model, p = 0.58 
Bold values indicate significant results  
 
Table 2. Demographics and clinical features in refractory and super-refractory SE 
 Univariate analysis 
 
Multiple stepwise logistic regression** 
 
RSE episodes  
(not becoming SRSE) 
(n=268) 
 SRSE episodes (n=33)  p-value Test  OR  95% CI  P-value 
 
Demographics*                  
   Incident SE patients (nr, %) 220   33.1%  29  4.4%           
   Age (years) (mean, SD) 64  ±18  52  ±19  <0.001 Student t  0.96  0.95 – 0.99  0.002  
   Female gender (nr, %) 104  47.3%  13   44.8%  0.804 Pearson χ2        
Earlier seizures (nr, %) 128   47.8%  16   48.5%  0.937 Pearson χ2        
Charlson Comorbidity Index 
(CCI) (median [range]) 0  0-8  1  0-12  0.15 U-test 
 
     
 
   CCI 0 (nr, %) 86  32%  17  51.5%           
   CCI ≥1 (nr, %) 182  68%  16  48.5%  0.026 Pearson χ2      NS  
Etiology according to ILAE (nr, %)                  
   Acute symptomatic 157   58.6%  19  57.6%           
   Remote symptomatic 33   12.3%  5  15.2%         NS  
   Progressive symptomatic 57  21.2%  6   18.2%           
   Cryptogenic/idiopathic 21   7.8%  3   9.0%  0.943 Pearson χ2      NS  
Potentially fatal etiology (nr, %) 138   51.5%  19  57.6%  0.509 Pearson χ2      NS  
Consiousness at SE onset (nr, %)                     
  Alert, confused or somnolent 104   38.8%  4  12.1%    
 
     
 
  Stuporous or comatose 164   61.2%  29  87.9%  0.003 Pearson χ2 
 
4.26  1.44 – 12.60  0.001 
 
SE types (nr, %)           
 
     
 
  Simple partial 40   14.9%  1  3.0%    
 
     
 
  Absence 1   0.4%  0       
 
     
 
  Complex partial 98  36.6%  10  30.3%    
 
     
 
Generalized myoclonic  0     0        
 
     
 
  Generalized convulsive  110  41.0%  15   45.5%    
 
     
 
  Nonconvulsive SE in coma 19   7.1%  7   21.2%  0.007 Fisher 
 
    NS 
 
STESS ≥ 3 (nr, %) 152   56.7%  20   60.6%  0.670 Pearson χ2 
 
     
 
Time to treatment > 1 h (nr, %) 171   63.8%  21   63.6%  0.958 Pearson χ2 
 




Intubation for treatment (nr, %) 46   16.0%  33  100%  <0.001 Pearson χ2 
 
     
 
Outcome at discharge (nr, %)                  
   Returned to baseline  100   37.8%  6   18.0%  0.030 Pearson χ2        
   New handicap 117   43.7%  16  48.5%  0.598 Pearson χ2        
   Death** 51   24.5%  11   37.9%  0.084 Pearson χ2        
  Death during SE (nr, %) 20   37%  8  72.7%  0.053 Fisher  
 
     
 
                
SD, standard deviation; CI, confidence interval; SE, status epilepticus; STESS, status epilepticus severity score. 
*Demographics and mortality frequency was calculated according to the number of the incident patients. 
**Hosmer–Lemeshow goodness-of-fit test for the final model, p = 0.49 
Bold values indicate significant results  
 











Italy (4) Hospital based, prospective 2013 – 2014  83 12 (14%) 7.7– 23.8 14 (17%) 9.5 – 26.7 
 
China  (17) Hospital based, retrospective 2009 – 2012  98 20 (20.4%) 12.9 – 29.7 12 (12.2%) 6.5 – 20.4 
Sweden (7) Hospital based, retrospective 2008 – 2012  103 59 (57%) 47.0 – 67.0 26 (25%) 17.2 – 34.7 
Argentina (8) Hospital based, prospective 2007 – 2012  311 109 (35%) 29.8 – 40.6 15 (5%) 2.7 – 7.3 
Switzerland (6) ICU-based, retrospective 2005 – 2011  171 63 (37%) 29.6 – 44.5 45 (26%) 19.9 – 33.6 
India (9) ICU-based, retrospective 2005 – 2013 177 42 (23.7%) 17.7 – 30.7 30 (16.9%) 
 






Hospital based, retrospective 2006 – 2015  804 268 (33.3%) 30.0 – 37.0 33 (4.1%) 2.5 – 5.7 










4 (1%) 33 (100%)46 (17%)
33% 4%63%
Figure 1: illustration of the distribution of Status epilepticus (SE) episodes according to
their refractoriness and need of mechanical ventilation.
